DGAP-News: CO.DON AG attended BIO CEO & Investor Conference in New York

CO.DON AG attended BIO CEO & Investor Conference in New York

Berlin / Teltow, 20 February 2019 - On 10 and 11 February 2019 the 21st BIO CEO & Investor Conference took place in New York. The annual BIO CEO & Investor Conference is one of the biggest investor conferences, focusing on established and emerging publicly listed and selected private biotech companies. Some 1,300 participants registered for this year's event, including around 660 investors.

More than 130 biotech and pharma companies gave 13-minute pitches to present their pipeline, R&D activities, business and investment targets. These were supplemented by more than 3,000 one-on-one meetings.

Ralf M. Jakobs, CEO of CO.DON AG, had many meetings to discuss various finance and partnership options for the company to gain access to the US market: "In the conversations I had it was made very clear to me that CO.DON AG is increasingly in the focus of major US-based investors and that there is also great interest on the part of potential business partners in the US. This is very good news, also because it is an acknowledgement of our work over the past 12 months to open up the European market by securing the reimbursement of treatment costs in our selected national markets. On the basis of these initial exploratory discussions we now intend to implement a follow-up plan to evaluate the opportunities."

CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 14,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product from the European Medicines Agency (EMA). The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Ralf M. Jakobs.

Further information is available from www.codon.de

Investor Relations and Press Contact:

Matthias Meißner, M.A.

Tel. +49 (0)30 240352330

Fax +49 (0)30 240352309

Email: ir@codon.de